Zai Lab Ltd (ZLAB)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: China
Exchange: NASDAQ
Market cap: $22.37B
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Latest financial period: June 30, 2026
Filed with the SEC: August 6, 2026
Estimated earnings date: November 5, 2026
Profit #1344 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 7.1% | 7.0% | 7.4% | 6.5% |
Growth #840 of 1484 companies
Payout #1117 of 1484 companies
Safety #1038 of 1484 companies
Price #1353 of 1484 companies
